US equities |
AAPL $331.90 ▼-1.90% NVDA $206.69 ▲+2.29% MU $855.10 ▲+2.58% AMD $483.90 ▲+3.65% ORCL $126.19 ▲+5.85% TSLA $398.50 ▼-1.32% MSFT $520.99 ▲+2.74% SPCX $141.31 ▲+3.62%
FinancialContent

InflaRx N.V. - Common Stock (NQ:IFRX)

1.620 -0.145 (-8.22%)
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about InflaRx N.V. - Common Stock

News headline image
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces November Investor Events
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx to Host Virtual Capital Markets Day
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Participation in September Investor Conferences
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
From InflaRx N.V.
Via GlobeNewswire
News headline image
Earnings Season: Synergy CHC (NASDAQ: SNYR) FOCUSfactor® Beverage – Eyes $100M+ in 2026 – More Stocks Reporting Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance
Via ACCESS Newswire
News headline image
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
From InflaRx N.V.
Via GlobeNewswire
Inflarx NV (NASDAQ: IFRX) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
From InflaRx N.V.
Via GlobeNewswire